712 North

Leading the Way How We Treat Neurodegeneration

712 North is a biopharmaceutical company developing drugs for patients with Alzheimer's disease and other neurodegenerative diseases.

We have identified a new, proprietary molecular mechanism-of-action in a rare genetic disease of childhood blindness with the name Autosomal Dominant Optic Atrophy.

We differentiate our selves in that we leverage the orphan childhood disease as fast-to-market solution thereby accelerating the development and approval process.